Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.

Lehmann BD, Abramson VG, Sanders M, Mayer EL, Haddad T, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA.

Clin Cancer Res. 2019 Dec 10. pii: clincanres.2170.2019. doi: 10.1158/1078-0432.CCR-19-2170. [Epub ahead of print]

PMID:
31822498
2.

Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.

Lee GE, Rosenberg SM, Mayer EL, Borges V, Meyer ME, Schapira L, Come SE, Partridge AH.

Breast J. 2019 Nov;25(6):1104-1110. doi: 10.1111/tbj.13431. Epub 2019 Jul 18.

PMID:
31318125
3.

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.

Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ.

Ann Oncol. 2019 Sep 1;30(9):1514-1520. doi: 10.1093/annonc/mdz198.

PMID:
31250880
4.

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.

Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM.

Clin Breast Cancer. 2019 Dec;19(6):399-404. doi: 10.1016/j.clbc.2019.05.010. Epub 2019 May 30.

PMID:
31235441
5.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
6.

[Psychopathy among inmate population in Argentina and Chile: Characterization and transnational norms].

Mayer EL, Hare RD, Folino JO.

Vertex. 2018 Jan;29(137):11-19. Spanish.

PMID:
30605189
7.

Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.

Kadish SS, Mayer EL, Jackman DM, Pomerantz M, Brady L, Dimitriadis A, Cleveland JLF, Wagner AJ.

J Oncol Pract. 2018 Jul;14(7):e421-e428. doi: 10.1200/JOP.18.00093. Epub 2018 Jun 25.

PMID:
29939808
8.

Randomized trial of a clinic-based weight loss intervention in cancer survivors.

Brown JC, Yung RL, Gobbie-Hurder A, Shockro L, O'Connor K, Campbell N, Kasper J, Mayer EL, Tolaney SM, Partridge AH, Ligibel JA.

J Cancer Surviv. 2018 Apr;12(2):186-195. doi: 10.1007/s11764-017-0657-5. Epub 2017 Nov 3.

9.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. Erratum in: Sci Transl Med. 2019 Feb 13;11(479):.

10.

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.

Wander SA, Mayer EL, Burstein HJ.

J Clin Oncol. 2017 Sep 1;35(25):2866-2870. doi: 10.1200/JCO.2017.73.9482. Epub 2017 Jun 3. Review.

PMID:
28580881
11.

Prognosis of pregnancy-associated breast cancer.

Lee GE, Mayer EL, Partridge A.

Breast Cancer Res Treat. 2017 Jun;163(3):417-421. doi: 10.1007/s10549-017-4224-6. Epub 2017 Apr 1. Review.

PMID:
28365832
12.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

13.

Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.

Johnson KE, Forward JA, Tippy MD, Ceglowski JR, El-Husayni S, Kulenthirarajan R, Machlus KR, Mayer EL, Italiano JE Jr, Battinelli EM.

Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):664-674. doi: 10.1161/ATVBAHA.116.308791. Epub 2017 Feb 2.

14.

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D.

J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.

PMID:
27918725
15.

Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.

Irwin ML, Cartmel B, Harrigan M, Li F, Sanft T, Shockro L, O'Connor K, Campbell N, Tolaney SM, Mayer EL, Yung R, Freedman RA, Partridge AH, Ligibel JA.

Cancer. 2017 Apr 1;123(7):1249-1258. doi: 10.1002/cncr.30456. Epub 2016 Nov 28.

16.

Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

Mayer EL, Burstein HJ.

J Clin Oncol. 2016 Oct 1;34(28):3369-71. doi: 10.1200/JCO.2016.68.4068. Epub 2016 Aug 22. No abstract available.

PMID:
27551109
17.

Immediate breast reconstruction following mastectomy in pregnant women with breast cancer.

Caragacianu DL, Mayer EL, Chun YS, Caterson S, Bellon JR, Wong JS, Troyan S, Rhei E, Dominici LS, Economy KE, Tung NM, Schapira L, Partridge A, Calvillo KZ.

J Surg Oncol. 2016 Aug;114(2):140-3. doi: 10.1002/jso.24308. Epub 2016 Jul 8.

PMID:
27392534
18.

Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.

Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH.

Oncologist. 2016 Jun;21(6):666-70. doi: 10.1634/theoncologist.2015-0449. Epub 2016 Apr 22.

19.

Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.

Mayer EL.

Clin Adv Hematol Oncol. 2015 Apr;13(4):215-7. No abstract available.

PMID:
26352578
20.

Adjuvant endocrine therapy for postmenopausal women: Type and duration.

Mayer EL, Burstein HJ.

Breast. 2015 Nov;24 Suppl 2:S126-8. doi: 10.1016/j.breast.2015.07.028. Epub 2015 Aug 14.

PMID:
26279133
21.

Postmenopausal breast cancer: a best endocrine strategy?

Mayer EL, Burstein HJ.

Lancet. 2015 Oct 3;386(10001):1317-1319. doi: 10.1016/S0140-6736(15)61206-5. Epub 2015 Jul 23. No abstract available.

22.

Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.

Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, Iliescu C, Ky B, Mayer EL, Okwuosa TM, Plana JC, Ryan TD, Rzeszut AK, Douglas PS.

J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46. doi: 10.1016/j.jacc.2015.04.059. Review.

23.

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP.

J Clin Oncol. 2015 Jul 20;33(21):2361-9. doi: 10.1200/JCO.2014.59.5298. Epub 2015 Jun 8.

24.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

25.

Targeting breast cancer with CDK inhibitors.

Mayer EL.

Curr Oncol Rep. 2015;17(5):443. doi: 10.1007/s11912-015-0443-3. Review.

PMID:
25716100
26.

Breast cancer axillary staging: much ado about micrometastatic disease.

Mayer EL, Dominici LS.

J Clin Oncol. 2015 Apr 1;33(10):1095-7. doi: 10.1200/JCO.2014.59.2303. Epub 2015 Feb 23. No abstract available.

PMID:
25713441
27.

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2015 Mar 1;21(5):1098-105. doi: 10.1158/1078-0432.CCR-14-1948. Epub 2014 Dec 18. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3356-7.

28.

Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.

Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ.

Clin Breast Cancer. 2015 Feb;15(1):24-30. doi: 10.1016/j.clbc.2014.07.010. Epub 2014 Aug 15.

PMID:
25205424
29.

Sentinel lymph node biopsy in pregnant women with breast cancer.

Gropper AB, Calvillo KZ, Dominici L, Troyan S, Rhei E, Economy KE, Tung NM, Schapira L, Meisel JL, Partridge AH, Mayer EL.

Ann Surg Oncol. 2014 Aug;21(8):2506-11. doi: 10.1245/s10434-014-3718-2. Epub 2014 Apr 23.

PMID:
24756813
30.

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.

Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP.

Breast Cancer Res Treat. 2013 Nov;142(2):405-14. doi: 10.1007/s10549-013-2754-0. Epub 2013 Nov 7.

PMID:
24197661
31.

Prospective clinical experience with research biopsies in breast cancer patients.

Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU.

Breast Cancer Res Treat. 2013 Nov;142(1):203-9. doi: 10.1007/s10549-013-2717-5. Epub 2013 Oct 11.

32.

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.

Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.

PMID:
24062210
33.

Reply to V. Pitini et al.

Mayer EL, Lin NU.

J Clin Oncol. 2013 Jun 10;31(17):2225-6. No abstract available.

PMID:
23901420
34.

Contemporary multidisciplinary treatment of pregnancy-associated breast cancer.

Meisel JL, Economy KE, Calvillo KZ, Schapira L, Tung NM, Gelber S, Kereakoglow S, Partridge AH, Mayer EL.

Springerplus. 2013 Jul 3;2(1):297. doi: 10.1186/2193-1801-2-297. Print 2013 Dec.

35.

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN.

Breast Cancer Res Treat. 2013 Jul;140(2):331-9. doi: 10.1007/s10549-013-2632-9. Epub 2013 Jul 19.

PMID:
23868188
36.

Early and late long-term effects of adjuvant chemotherapy.

Mayer EL.

Am Soc Clin Oncol Educ Book. 2013:9-14. doi: 10.1200/EdBook_AM.2013.33.9.

37.

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.

Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ.

Breast Cancer Res Treat. 2013 Jun;139(2):403-10. doi: 10.1007/s10549-013-2551-9. Epub 2013 May 5.

PMID:
23645007
38.

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.

Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ.

Breast Cancer Res Treat. 2012 Nov;136(1):169-78. doi: 10.1007/s10549-012-2256-5. Epub 2012 Sep 23.

39.

Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?

Mayer EL, Lin NU.

J Clin Oncol. 2012 Nov 1;30(31):3769-72. doi: 10.1200/JCO.2012.44.9611. Epub 2012 Sep 17. No abstract available.

PMID:
22987088
40.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

41.

Breast cancer survivors' perceptions of survivorship care options.

Mayer EL, Gropper AB, Neville BA, Partridge AH, Cameron DB, Winer EP, Earle CC.

J Clin Oncol. 2012 Jan 10;30(2):158-63. doi: 10.1200/JCO.2011.36.9264. Epub 2011 Dec 12.

42.

A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A.

Clin Cancer Res. 2011 Nov 1;17(21):6897-904. doi: 10.1158/1078-0432.CCR-11-0070. Epub 2011 Sep 8.

43.

Juvenile offenders assessment.

Folino JO, Mayer EL.

Curr Opin Psychiatry. 2011 Sep;24(5):436-41. doi: 10.1097/YCO.0b013e328349bb92. Review.

PMID:
21788899
44.

Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.

Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA.

Hypertension. 2011 Jul;58(1):85-92. doi: 10.1161/HYPERTENSIONAHA.110.168120. Epub 2011 Apr 11.

45.

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA.

J Clin Oncol. 2011 Feb 20;29(6):632-8. doi: 10.1200/JCO.2010.31.9129. Epub 2011 Jan 4.

PMID:
21205755
46.

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A.

Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):94-104. doi: 10.1016/j.pcad.2010.05.006. Review.

PMID:
20728696
47.

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Mayer EL, Krop IE.

Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834. Review.

48.

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.

Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ.

Ann Oncol. 2010 Dec;21(12):2370-6. doi: 10.1093/annonc/mdq260. Epub 2010 May 23.

PMID:
20497961
49.

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP.

Breast Cancer Res Treat. 2009 Oct;117(3):615-23. doi: 10.1007/s10549-009-0366-5. Epub 2009 Mar 18.

50.

Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.

Mayer EL, Burstein HJ.

J Clin Oncol. 2008 Mar 10;26(8):1198-200. doi: 10.1200/JCO.2007.14.8734. No abstract available.

PMID:
18323544

Supplemental Content

Loading ...
Support Center